Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events
Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events
复制标题
DOI：
10.1080/00016489.2020.1807601
复制
发表时间：
2020-08-14
影响因子：
1.4
通讯作者：
Nakagawa, Takashi
中科院分区：
文献类型：
--
作者：
Yasumatsu, Ryuji;Matsuo, Mioko;Nakagawa, Takashi
背景：有时会发生需要停止治疗的重大免疫相关不良事件（irAE）。irAE后中止治疗对疾病控制的影响尚不清楚。目的：本研究的目的是调查患者在irAE后停止治疗后是否继续显示出反应或持久的疾病控制。材料和方法：对14名停止治疗而无进展的患者检查了纳武单抗单药治疗中止后的反应。结果：最佳缓解为CR 5例（36%），PR 8例（57%），SD 1例（7%）。估计的1年总生存率和无进展生存率分别为92.9%和78.6%。在发生PD的患者中，nivolumab治疗期间的最佳反应为5例患者中的0例（0%）为CR，8例患者中的3例（38%）为PR，1例患者（100%）为SD。获得CR的患者往往有较低的PD风险比那些PR或SD.Conclusions和意义：CR状态的患者可能会继续表现出反应或持久的疾病控制，即使停止治疗后，由于irAE。
Background: Significant immune-related adverse events (irAEs) requiring therapy discontinuation sometimes occur. The influence of discontinuation on disease control after an irAE is unclear.Objectives: The aim of this study was to investigate whether or not patients continued to show a response or durable disease control even after stopping therapy following an irAE.Material and Methods: The response after nivolumab monotherapy discontinuation was examined for 14 patients in whom therapy was stopped without progression.Results: The best response was CR in 5 (36%) patients, PR in 8 (57%) patients and SD in 1 (7%) patient. The estimated 1-year overall and progression-free survival rates were 92.9% and 78.6%, respectively. The best response during nivolumab therapy in patients who developed PD was CR in 0 of 5 patients (0%), PR in 3 of 8 patients (38%) and SD in 1 patient (100%). Patients obtaining CR tended to have a lower risk of PD than those with PR or SD.Conclusions and Significance: Patients with CR status may continue to show a response or durable disease control even after stopping therapy due to an irAE.